Birch Capital Management LLC Sells 5,510 Shares of Novo Nordisk A/S (NYSE:NVO)

Birch Capital Management LLC decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 134,623 shares of the company’s stock after selling 5,510 shares during the quarter. Novo Nordisk A/S comprises approximately 5.8% of Birch Capital Management LLC’s investment portfolio, making the stock its 4th largest position. Birch Capital Management LLC’s holdings in Novo Nordisk A/S were worth $11,580,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Natixis Advisors LLC grew its holdings in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after acquiring an additional 80,070 shares during the period. Versant Capital Management Inc acquired a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $86,000. Norman Fields Gottscho Capital Management LLC increased its holdings in Novo Nordisk A/S by 45.3% in the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after purchasing an additional 19,870 shares in the last quarter. Zions Bancorporation N.A. lifted its stake in Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after buying an additional 6,726 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of Novo Nordisk A/S by 14.8% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after buying an additional 37,346 shares during the period. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Down 2.4 %

NYSE:NVO traded down $2.03 on Tuesday, hitting $83.00. The stock had a trading volume of 6,231,371 shares, compared to its average volume of 6,209,503. Novo Nordisk A/S has a 1 year low of $81.50 and a 1 year high of $148.15. The firm’s fifty day simple moving average is $102.51 and its two-hundred day simple moving average is $120.68. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a market cap of $372.47 billion, a P/E ratio of 26.86, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.